D.C. Lung Cancer Conference 2022


D.C. Lung Cancer Conference 2022 Banner

Add to Calendar D.C. Lung Cancer Conference 2022 10/29/2022 8:00:00 AM 10/29/2022 5:05:00 PM America/New_York For More Details: https://medstar.cloud-cme.com/course/courseoverview?EID=18667 Description: Registration is closed until 8:00 AM on October 29, 2022 onsite at Pooks Hill Marriott, Bethesda, MD.This one-day symposium will provide an update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer manageme... Pooks Hill Marriott false MM/DD/YYYY


Date & Location
Saturday, October 29, 2022, 8:00 AM - 5:05 PM, Pooks Hill Marriott, Bethesda, MD

Target Audience
Specialties - Internal Medicine, Medical Oncology, Oncology, Pathology, Pulmonology, Radiation Oncology, Radiology, Surgery
Professions - Non-Physician, Nurse, Pharmacist, Physician, Student

Overview

Registration is closed until  8:00 AM on October 29, 2022 onsite at Pooks Hill Marriott, Bethesda, MD.

 

This one-day symposium will provide an update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection, to diagnosis to treatment. This symposium will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact didactic talks will be delivered by national thought leaders and well-respected faculty in each field. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on proton beam radiation, minimally invasive surgery and immunotherapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over neoadjuvant vs adjuvant immunotherapy for resectable NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions and through a case-based format following each session with access to presentation materials for later review.

 

Endorsed by:


Objectives
After completing this activity, the participant will be able to:

  1. Identify the benefit of CT screening for lung cancer.
  2. Discuss the current application of liquid biopsy (or ctDNA analysis).
  3. Explain the approved adjuvant and neoadjuvant treatment options for resectable, driver negative non-small cell lung cancer.
  4. Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
  5. Describe the benefit of immunotherapy in the treatment of small cell lung cancer.
  6. Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
  7. Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
  8. Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer.
  9. Discuss management of immune-mediated toxicities.
  10. Identify nursing strategies for early detection of immune-mediated toxicities.
  11. Recognize unique toxicities associated with targeted agents used in NSCLC.
  12. Recognize common immune related adverse events and factors that increase patient risk.
  13. Discuss standard targeted agents in use for patients with driver-positive non-small cell lung cancer.
  14. Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer.
  15. Identify the pharmacologic management of immune-mediated adverse events based on current guidelines and evidence.
  16. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with lung cancer.
  17. Integrate a team-based approach in the care of patients with lung cancer.

Registration
  • Physician $175
  • IASLC Member  $140
  • Resident/Fellow $100
  • Physician Assistant $100
  • Nurse Practitioner $100
  • Nurse $100
  • Pharmacist $100
  • Allied Health Professional $100
  • Industry Professional $250

 


Accreditation

 In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation Statement

This activity was planned by and for the healthcare team and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

 

Physicians: MedStar Health designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses: This activity is approved for 6.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 6.25 contact hours. This learning activity is knowledge-based. The Universal Activity Number for this program is UAN# JA4008151-0000-22-014-L05-P


Credits
AMA PRA Category 1 Credits™ Physician (6.25 hours), IPCE (6.25 hours), Non-Physician Member of the Healthcare Team (6.25 hours), Nurse - ANCC (6.25 hours), Pharmacist - ACPE (6.25 hours)